## **Specimen Collection and Processing Form**

PPMI Syn One: Case Report Form	
Site No:	<ul> <li>018 - University of Pennsylvania</li> <li>034 - Institute for Neurodegenerative Disorders</li> <li>088 - Northwestern University</li> </ul>
Email address of staff member completing this form:	
Note: A copy of the completed CRF will be sent to this address.	
PPMI Participant ID:	
Sex	<ul><li>○ Female</li><li>○ Male</li></ul>
Year of Birth	
PPMI Visit ID:	○ BL         ○ V04         ○ V05         ○ V08         ○ V10         ○ V12         ○ V13         ○ V14         ○ V15         ○ V16         ○ V17         ○ V18         ○ V19         ○ V20         ○ V21         ○ V22
PPMI Visit Date:	
Consent and Eligibility	
PPMI SynOne ICF Site Version Date:	
PPMI SynOne ICF Study Version Date:	
PPMI SynOne Date of Consent:	

Did the participant consent to receive the results of their SynOne test:	○ Yes ○ No
Did participant meet the below PPMI SynOne eligibility criteria?	
Inclusion Criteria:	
<ul> <li>Willing and able to provide written informed consent.</li> <li>Enrolled in PPMI clinical study.</li> <li>PPMI clinical participants with already-available SAA results. Exclusion Criteria:</li> </ul>	
- History of allergic reaction to local anesthesia for skin biopsies.	
<ul> <li>Use of anticoagulants, including but not limited to the following medications, are excluded from this study: Dabigatran (PRADAXA, PRADAX, PRAZAXA), HEPARIN, Warfarin (COUMADIN, JANTOVEN), Lepirudan (REFLUDAN), Bivalirudin (ANGIOMAX), and Desirudin (LPRIVASK).</li> <li>Significantly impaired wound health or history of scarring or keloid formation.</li> </ul>	
Reason Ineligible:	<ul> <li>Not enrolled in PPMI Clinical</li> <li>Unable to provide informed consent</li> <li>Unwilling to provide informed consent</li> <li>History of allergic reaction to local anesthesia.</li> <li>Use of anticoagulants, including but not limited to the following medications, are excluded from this study: Dabigatran (PRADAXA, PRADAX, PRAZAXA), HEPARIN, Warfarin (COUMADIN, JANTOVEN), Lepirudan (REFLUDAN), Bivalirudin (ANGIOMAX), and Desirudin (LPRIVASK).</li> <li>Significantly impaired wound health or history of scarring or keloid formation</li> <li>Other</li> <li>(Please click "submit" below after entering the Reason Ineligible)</li> </ul>
Please Specify:	
Biopsy Collection Detail	
Date of biopsy collection:	
Time of biopsy collection:	(Use 24 Hour clock.)
Side of body:	○ RIGHT ○ LEFT

Biopsies Collected	<ul> <li>No</li> <li>Collected</li> <li>Partial Collection</li> <li>Attempted, No Collection</li> <li>(If response is "No", "Partial Collection", or "Attempted, No Collection", please specify in comments)</li> </ul>	
Biopsies Collected:	<ul><li>☐ Distal Leg (10 cm above the lateral malleolus)</li><li>☐ Distal Thigh (10 cm above the lateral knee)</li></ul>	
Note: Expected number of biopsies is 3.	<ul> <li>Posterior Cervical Region (3 cm lateral to the C-7 spinous process)</li> </ul>	
Reason fewer biopsies were collected than expected:		
Notes:		

## [patno] SynOne Pathology Report AE Form

PPMI Syn One: Adverse Events Log	
Site No: [cno] Participant ID: [patno] Collection Date: [skndrdt]	
AE #1	
AE #1 Start Date	
AE #1 Stop Date	
AE #1 Detail	
AE #1 Severity	<ul><li>○ 1 - mild</li><li>○ 2 - moderate</li><li>○ 3 - severe</li></ul>
AE #1 Serious	<ul><li>Yes</li><li>No</li></ul>
AE #1 Relationship to Study	<ul> <li>1 - unrelated</li> <li>2 - unlikely</li> <li>3 - possible</li> <li>4 - probable</li> <li>5 - definite</li> </ul>
AE #1 Resulted in Study Withdrawal	○ Yes ○ No
AE #1 Primary Outcome	<ul> <li>1 - recovered</li> <li>2 - under treatment/observation</li> <li>3 - change in AE characteristic</li> <li>4 - sequela</li> <li>5 - fatal</li> <li>6 - unknown</li> </ul>
AE #1 Notes	
Additional AE incident?	○ Yes ○ No

AE #2	
AE #2 Start Date	
AE #2 Stop Date	
AE #2 Detail	
AE #2 Severity	<ul><li>1 - mild</li><li>2 - moderate</li><li>3 - severe</li></ul>
AE #2 Serious	
AE #2 Relationship to Study	<ul> <li>1 - unrelated</li> <li>2 - unlikely</li> <li>3 - possible</li> <li>4 - probable</li> <li>5 - definite</li> </ul>
AE #2 Resulted in Study Withdrawal	○ Yes ○ No
AE #2 Primary Outcome	<ul> <li>1 - recovered</li> <li>2 - under treatment/observation</li> <li>3 - change in AE characteristic</li> <li>4 - sequela</li> <li>5 - fatal</li> <li>6 - unknown</li> </ul>
AE #2 Notes	

## [patno] SynOne Pathology Report Results Form

PPMI Syn One: Pathology Results	
Site No: [cno] Participant ID: [patno] Collection Date: [skndrdt]	
Please upload a copy of the SynOne Pathology Report	
Conclusions	
Pathology Report Conclusions: Synucleinopathy	<ul> <li>No evidence of phosphorylated alpha-synuclein deposition</li> <li>Pathologic evidence of phosphorylated alpha-synuclein deposition within cutaneous nerve</li> <li>Other</li> </ul>
Please Specify:	
Pathology Report Conclusions: Small Fiber Neuropathy	<ul> <li>Normal intraepidermal nerve fiber density.</li> <li>Reduced intraepidermal nerve fiber density consistent with a length dependent small fiber neuropathy.</li> <li>Other</li> </ul>
Please Specify:	
Macroscopic Description and Processing	
All biopsies were reported in adequate condition	○ Yes ○ No
Example:	
Macroscopic Description and Processing  Three (3) skin biopsies in Zamboni fixative were received. The vials distal leg and biopsies were measured to be 3 mm. The biopsies were the biopsies were sectioned into 50 μm samples. The following stains 1. Standard dual immunostaining with protein gene product 9 2. Standard Congo Red staining 3. Standard hematoxylin and eosin staining	ere in adequate condition. They were washed and cryoprotected. ins were performed:
Please indicate which biopsies were reported as not adequate:	☐ Post Cervical ☐ Distal Thigh ☐ Distal Leg (check all that apply)

**₹EDCap**°

09/09/2025 1:54pm

1 2 4

Microscopic Description			
Enter Normal/Abnormal as indicated on the Results Report			
Phosphorylated Alpha-Synuclein	Normal	Abnormal	Benign Findings
Intraepidermal Nerve Fibers	0	0	0
Skin Histology (Hematoxylin and Eosin)	0	0	0
Pathology Results - Phosphoryl	ated Alpha-Syn	uclein (P-Syn)	
P-syn Deposition - Post Cervical:		<ul> <li>No phosphorylated alp observed in stained sections.</li> <li>Two or more colocalized stained sections.</li> <li>At least one (1) colocatiber observed in every observed in every stained sections.</li> </ul>	ections. seen across all stained ed fibers seen across all dized P-Syn positive nerve y stained section. Syn positive nerve fiber
P-syn Deposition - Distal Thigh		<ul> <li>No phosphorylated alpobserved in stained sections.</li> <li>One colocalized fiber sections.</li> <li>Two or more colocalized stained sections.</li> <li>At least one (1) colocation fiber observed in every observed in every stained sections.</li> </ul>	ections. seen across all stained ed fibers seen across all dized P-Syn positive nerve y stained section. Syn positive nerve fiber
P-syn Deposition - Distal Leg		<ul> <li>No phosphorylated alpobserved in stained sections.</li> <li>Two or more colocalized stained sections.</li> <li>At least one (1) colocatiber observed in every observed in every stained sections.</li> </ul>	ections. seen across all stained ed fibers seen across all lized P-Syn positive nerve y stained section. Syn positive nerve fiber
Pathology Results - Intraepider	mal Nerve Fibe	r Density	
Observed Measurement - Post Cervical	:		
Normal Range - Post Cervical:			
		(Enter Numbers Only, Do Than/Equal To sign)	not enter Greater
Observed Measurement - Distal Thigh			
			<del></del>

Normal Range - Distal Thigh	
	(Enter Numbers Only, Do not enter Greater Than/Equal To sign)
Observed Measurement - Distal Leg	
Normal Range - Distal Leg	
	(Enter Numbers Only, Do not enter Greater Than/Equal To sign)

**₹EDCap**°

09/09/2025 1:54pm projectredcap.org